Lv1
60 积分 2024-10-17 加入
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
4天前
已完结
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database
9天前
已关闭
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
9天前
已完结
Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)
9天前
已完结
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
10天前
已完结
Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis
10天前
已完结
Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
10天前
已完结
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review
10天前
已完结
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis
10天前
已完结
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
10天前
已完结
皖公网安备34019202002308
